Skip to main navigation Skip to search Skip to main content

Comprehensive genomic analysis of patients with disorders of cerebral cortical development

  • Wojciech Wiszniewski
  • , Pawel Gawlinski
  • , Tomasz Gambin
  • , Monika Bekiesinska-Figatowska
  • , Ewa Obersztyn
  • , Dorota Antczak-Marach
  • , Zeynep Hande Coban Akdemir
  • , Tamar Harel
  • , Ender Karaca
  • , Marta Jurek
  • , Katarzyna Sobecka
  • , Beata Nowakowska
  • , Malgorzata Kruk
  • , Iwona Terczynska
  • , Alicja Goszczanska-Ciuchta
  • , Mariola Rudzka-Dybala
  • , Ewa Jamroz
  • , Antoni Pyrkosz
  • , Anna Jakubiuk-Tomaszuk
  • , Piotr Iwanowski
  • Dorota Gieruszczak-Bialek, Malgorzata Piotrowicz, Maria Sasiadek, Iwona Kochanowska, Barbara Gurda, Barbara Steinborn, Mateusz Dawidziuk, Jennifer Castaneda, Pawel Wlasienko, Natalia Bezniakow, Shalini N. Jhangiani, Dorota Hoffman-Zacharska, Jerzy Bal, Elzbieta Szczepanik, Eric Boerwinkle, Richard A. Gibbs, James R. Lupski

Research output: Contribution to journalArticlepeer-review

Abstract

Malformations of cortical development (MCDs) manifest with structural brain anomalies that lead to neurologic sequelae, including epilepsy, cerebral palsy, developmental delay, and intellectual disability. To investigate the underlying genetic architecture of patients with disorders of cerebral cortical development, a cohort of 54 patients demonstrating neuroradiologic signs of MCDs was investigated. Individual genomes were interrogated for single-nucleotide variants (SNV) and copy number variants (CNV) with whole-exome sequencing and chromosomal microarray studies. Variation affecting known MCDs-associated genes was found in 16/54 cases, including 11 patients with SNV, 2 patients with CNV, and 3 patients with both CNV and SNV, at distinct loci. Diagnostic pathogenic SNV and potentially damaging variants of unknown significance (VUS) were identified in two groups of seven individuals each. We demonstrated that de novo variants are important among patients with MCDs as they were identified in 10/16 individuals with a molecular diagnosis. Three patients showed changes in known MCDs genes and a clinical phenotype beyond the usual characteristics observed, i.e., phenotypic expansion, for a particular known disease gene clinical entity. We also discovered 2 likely candidate genes, CDH4, and ASTN1, with human and animal studies supporting their roles in brain development, and 5 potential candidate genes. Our findings emphasize genetic heterogeneity of MCDs disorders and postulate potential novel candidate genes involved in cerebral cortical development.

Original languageEnglish (US)
Pages (from-to)1121-1131
Number of pages11
JournalEuropean Journal of Human Genetics
Volume26
Issue number8
DOIs
StatePublished - Aug 1 2018

Funding

Acknowledgements This work was supported by the Career Development Award K23 NS078056 from the US National Institute of Neurological Disease and Stroke (NINDS) and National Science Centre, Poland 2015/19/B/NZ2/01824 to W.W., NIH/NIGMS T32 GM07526 Medical Genetics Research Fellowship Program to T.H., NINDS grants RO1 NS058529 and R35 NS105078 to JRL and the US National Human Genome Research Institute (NHGRI) National Heart Lung and Blood Institute (NHLBI) grant UM1 HG006542 to the Baylor-Hopkins Center for Mendelian Genomics.

FundersFunder number
Baylor-Hopkins Center for Mendelian Genomics
NIH/NIGMST32 GM07526, R35 NS105078, RO1 NS058529
US National Institute of Neurological Disease and Stroke
National Institute of Health National Heart, Lung, and Blood InstituteUM1 HG006542
National Human Genome Research Institute
National Institute of Neurological Disorders and StrokeK23NS078056
Narodowe Centrum Nauki2015/19/B/NZ2/01824

    ASJC Scopus subject areas

    • Genetics
    • Genetics(clinical)

    Fingerprint

    Dive into the research topics of 'Comprehensive genomic analysis of patients with disorders of cerebral cortical development'. Together they form a unique fingerprint.

    Cite this